Replies to post #129496 on Biotech Values

[genisi]

All told, I do not expect the CONFIRM study to have much impact, if any, on Copaxone sales.

Assuming BG-12 is approved for 1st line (almost certain, imo), with current safety/efficacy profile, you don't think it will take market share and impact Copaxone sales? I do agree it won't happen in a day but cannot see how Copaxone sales will not decline whith BG-12 as a competitor.